Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Merck KGaA predicts strong earnings growth on lab demand

Published 03/03/2022, 06:14
Updated 03/03/2022, 07:36
© Reuters. FILE PHOTO: A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016.  REUTERS/Ralph Orlowski
MRK
-
MRCG
-
MKKGY
-
MRCK34
-

By Ludwig Burger

FRANKFURT (Reuters) -Germany's Merck KGaA expects strong earnings growth this year as its laboratory gear division benefits from drugmakers' efforts to explore new biotechnologies, even as demand related to COVID-19 has probably reached its peak.

In a statement on Thursday, the diversified group predicted strong growth, excluding the effect of currency swings and any acquisitions, for sales and adjusted earnings before interest, tax, depreciation and amortisation (EBITDA).

"Life Science will remain the strongest growth engine for Merck," said the company, which also makes pharmaceuticals and speciality chemicals for semiconductor manufacturers.

Fourth-quarter adjusted EBITDA rose 17.6% to 1.46 billion euros ($1.62 billion), slightly below an analyst consensus of 1.48 billion euros posted on Merck's website.

The Life Science division, mostly comprising businesses previously known as Millipore and Sigma Aldrich, achieved a more than 28% jump in quarterly adjusted earnings on buoyant demand for bioreactor equipment.

The group's strong outlook comes despite a levelling off in demand related to COVID-19 vaccines and treatments.

COVID-related sales accounted for 1.15 billion euros of sales of 9 billion at the Life Science division in 2021, but that contribution will be about 900 million at most this year, according to a presentation posted on its website.

© Reuters. FILE PHOTO: A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016.  REUTERS/Ralph Orlowski

The group is helping biopharmaceutical companies to develop and produce new substances such as messenger RNA, targeted cancer treatments known as antibody-drug conjugates and viral vectors for gene therapies.

($1 = 0.9010 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.